ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks
Phase 3negativefirmonertinibNegative
AI Analysis
Summary
ArriVent BioPharma's lead lung cancer drug firmonertinib, an EGFR inhibitor, failed its Phase 3 trial, resulting in significant stock decline. The failure represents a major setback for the company's clinical pipeline.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed Phase 3 trial
Importance:8/10
Sentiment:
-0.90
Phase 3 failureEGFR inhibitorlung cancerstock decline
Related Companies
Read the original article
Published by Endpoints News on October 6, 2026 2:47 PM